GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: MDVN
Hold $45

MEDIVATION INC (NASDAQ: MDVN) downgraded to Hold with price target $45 by Canaccord Genuity

Wednesday,  Jan 27, 2016  9:25 AM ET by Betsy O'Brien Harrison

Canaccord Genuity downgraded MEDIVATION INC (NASDAQ: MDVN) to Hold with price target
$45. Previously Canaccord Genuity downgraded to MEDIVATION INC (NASDAQ: MDVN) to Buy with price target $180 on 04/08/2015, when the stock price was $129.60.

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three medical needs: Alzheimer?s disease, Huntington?s disease and castration-resistant prostate cancer. The Company has formed separate subsidiaries to hold the product candidates it is developing. The Company?s subsidiary Medivation Neurology, Inc. holds its Dimebon technology, and its subsidiary Medivation Prostate Therapeutics, Inc. holds its MDV300 series technology.

Canaccord Genuity’s global team of over 100 research professionals are inquisitive, experienced and committed to generating actionable investment ideas. We analyze over 725 companies in a broad range of market sectors, identifying value and defining risk for our clients.



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy